NewsBenzingaCapri Holdings alza la guidance dell’EPS GAAP per il FY2027 da $2,15 a $2,20 contro stima di $2,04; alza la guidance delle vendite per il FY2027 da $3,400 miliardi a $3,420 miliardi contro stima di $3,402 miliardi Capri Holdings alza la guidance dell’EPS GAAP per il FY2027 da $2,15 a $2,20 contro stima di $2,04; alza la guidance delle vendite per il FY2027 da $3,400 miliardi a $3,420 miliardi contro stima di $3,402 miliardi Benzinga 2026.10.30 11:02 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients